# Clevidence > Clevidence, Lda. is a Portuguese health consultancy specialised in Health Technology Assessment (HTA), market access, health economics and outcomes research (HEOR), real-world evidence and value communication, supporting academia, healthcare providers, government bodies and pharmaceutical companies with evidence-based decisions. Offices: Taguspark, Av. Jacques Delors, Edifício Inovação II, 411-421, 2740-122 Porto Salvo, Portugal; IPN Incubadora, Rua Pedro Nunes, 3000-199 Coimbra, Portugal. Contact: clevidence@clevidence.pt, +351 913 852 490. Languages: English (default) and Portuguese (/pt-pt/). ## Services - [Evidence Review, Synthesis and Generation](https://clevidence.pt/evidence-review-synthesis-e-generation/): Uncover powerful approaches in evidence review, synthesis and generation designed to deliver reliable, actionable intelligence. Portuguese version: [Revisão de Evidência, Síntese e Geração](https://clevidence.pt/pt-pt/revisao-de-evidencias-sintese-e-geracao/) - [Health Technology Assessment [HTA] and Market Access](https://clevidence.pt/health-technology-assessment-hta-and-market-access/): Explore how effective Health Technology Assessment (HTA) and integrated Market Access strategies ensure evidence-based decisions. Portuguese version: [Avaliação das tecnologias da saúde [ATS] e acesso ao mercado](https://clevidence.pt/pt-pt/avaliacao-das-tecnologias-da-saude-ats-e-acesso-ao-mercado/) - [Health Economics and Outcomes Research (HEOR)](https://clevidence.pt/health-economics-and-outcomes-research-heor/): Health Economics and Outcomes Research supports Market Access by demonstrating clinical and economic value, using real-world evidence and patient outcomes. Portuguese version: [Economia da Saúde e Investigação de Resultados (HEOR)](https://clevidence.pt/pt-pt/economia-da-saude-e-investigacao-de-resultados-heor/) - [Data Analytics and Real-World Evidence](https://clevidence.pt/data-analytics-and-real-world-evidence/): Data Analytics and Real-World Evidence to evaluate interventions, support market access, and generate actionable insights for health decision-making. Portuguese version: [Análise de dados e provas do mundo real](https://clevidence.pt/pt-pt/analise-de-dados-e-provas-do-mundo-real/) - [Communicating values and medical writing](https://clevidence.pt/value-communication-and-medical-writing/): Explore how value communication through expert medical writing ensures clarity, integrity and ethical precision in healthcare communication. Portuguese version: [Comunicação de valores e redação médica](https://clevidence.pt/pt-pt/comunicacao-de-valores-e-redacao-medica/) ## Case studies - [Integrated Support for the HTA and Reimbursement Process in Portugal](https://clevidence.pt/integrated-support-for-the-ats-process-and-financing-in-portugal/): Case study: end-to-end support for the HTA and reimbursement process in Portugal for a pulmonary infection medicine, from PICO to dossier. - [Localising a Cost Calculator to Support Market Access in Portugal](https://clevidence.pt/localising-a-cost-calculator-to-support-market-access-in-portugal/): Case study: localising a cost calculator to the Portuguese NHS to show the economic impact of a new therapy and support market access. - [Translating Respiratory Disease Evidence into Medical Education](https://clevidence.pt/translating-respiratory-disease-evidence-into-medical-education/): Case study: turning scattered evidence on a progressive respiratory disease and its comorbidities into medical education for Portuguese physicians. - [Validation of health economic model assumptions through expert elicitation](https://clevidence.pt/validation-of-health-economic-model-assumptions-through-expert-elicitation/): Case study: expert elicitation to validate cost-effectiveness and budget impact model assumptions for a renal disease treatment in Portugal. - [Advanced indirect comparisons to support HTA decision-making](https://clevidence.pt/advanced-indirect-comparisons-to-support-hta-decision-making/): A population-adjusted indirect comparison framework addressed heterogeneous evidence and supported HTA decision-making for a rare genetic disease therapy. - [Statin Safety Evidence, Clarified: An Umbrella Review for Scientific Communication](https://clevidence.pt/statin-safety-evidence-clarified-an-umbrella-review-for-scientific-communication/): An umbrella review consolidated statin safety evidence from systematic reviews and meta-analyses, enabling clear scientific communication and HCP engagement. - [Bridging the Evidence Gap in HTA: Indirect Comparisons to Support Reimbursement Decision-Making](https://clevidence.pt/bridging-the-evidence-gap-in-hta-indirect-comparisons-to-support-reimbursement-decision-making/): Case study: indirect treatment comparisons aligned with the HTA PICO framework to close the evidence gap and support a reimbursement decision. - [Evaluating the Impact of the COVID-19 Pandemic on NHS Cancer Screening and Outcomes](https://clevidence.pt/evaluating-the-impact-of-the-covid-19-pandemic-on-nhs-cancer-screening-and-outcomes/): Case study: how the COVID-19 pandemic affected NHS breast, cervical and colorectal cancer screening, and its impact on cancer outcomes. - [Enhancing Awareness of the Relationship Between Two Clinical Conditions](https://clevidence.pt/enhancing-awareness-of-the-relationship-between-two-clinical-conditions/): Case study: scoping review and slide deck to raise awareness of the relationship between two clinical conditions in medical and scientific meetings. - [Cost-Effectiveness Assessment for an Orphan Drug in a Rare Autoimmune Disease](https://clevidence.pt/cost-effectiveness-assessment-for-an-orphan-drug-in-a-rare-autoimmune-disease/): Case study: adapting a cost-effectiveness model for an orphan drug in a rare autoimmune disease, with ICER, budget impact and NHS pricing support. - [Comparative Effectiveness of Treatment Options for Advanced Stage Cancer with Genetic Alterations to Support HTA](https://clevidence.pt/comparative-effectiveness-of-treatment-options-for-advanced-stage-cancer-with-genetic-alterations-to-support-hta/): Case study: a systematic literature review of clinical evidence on a novel treatment for advanced cancer with genetic alterations, to support HTA. ## Insights - [What is the EU Joint Clinical Assessment (JCA) and how to prepare?](https://clevidence.pt/what-is-the-eu-joint-clinical-assessment-jca/): The EU Joint Clinical Assessment explained: products in scope from 2025 to 2030, how PICO scoping and the dossier work, and how to prepare. - [Budget impact analysis in Portugal: what INFARMED expects](https://clevidence.pt/budget-impact-analysis-in-portugal/): How to build a budget impact analysis for Portugal: SNS perspective, eligible population, time horizon and costs, following INFARMED guidelines. - [Indirect treatment comparisons in HTA: Bucher, NMA, MAIC and STC](https://clevidence.pt/indirect-treatment-comparisons-in-hta/): Indirect treatment comparisons in HTA explained: when to use the Bucher method, network meta-analysis, MAIC or STC, and which assumptions to check. - [Health technology assessment in Portugal: what changes with the new SiNATS](https://clevidence.pt/health-technology-assessment-in-portugal-new-sinats/): How HTA works in Portugal and what changes with the new SiNATS (Decree-Law 118/2026): scope, deadlines, real-world data and the link with the EU JCA. - [How do Systematic Literature Reviews support HTA?](https://clevidence.pt/how-do-systematic-literature-reviews-support-hta/): How systematic literature reviews support HTA with transparent, reproducible evidence for clinical, safety, economic and reimbursement decisions. - [What is the difference between Cost-Effectiveness Analysis and Budget Impact Analysis?](https://clevidence.pt/what-is-the-difference-between-cost-effectiveness-analysis-and-budget-impact-analysis/): Understand the difference between cost-effectiveness analysis and budget impact analysis in HTA, reimbursement and market access. - [How does Real-World Evidence support HTA?](https://clevidence.pt/how-does-real-world-evidence-support-hta/): Learn how real-world evidence supports HTA, reimbursement, market access and healthcare decision-making beyond clinical trials. - [What is Evidence Gap Analysis in HTA?](https://clevidence.pt/what-is-evidence-gap-analysis-in-hta/): Evidence gap analysis identifies missing or weak evidence before an HTA, reimbursement submission or market access strategy. See how it works. - [What is Health Technology Assessment?](https://clevidence.pt/what-is-health-technology-assessment-hta/): Understand why HTA is vital for market access and how Clevidence supports your reimbursement strategy. Learn more. ## About and contact - [About Clevidence](https://clevidence.pt/about-us/): About Us: we deliver rigorous HTA, R&D, and market access support, driven by integrity, innovation, and a client-focused approach to healthcare. - [Contact](https://clevidence.pt/contact-us/) - [Services overview](https://clevidence.pt/services/): Explore expert-led services in health economics, HTA, real-world evidence and value communication. Empower better decisions across healthcare markets.